Laboratorios Farmaceuticos ROVI (ROVI.MC) Aktie Kurs
Laboratorios Farmaceuticos ROVI Kurs
Omsætningen er vokset med 12,6 % om året de seneste 19 år til 743,48 Mio. EUR. Indtjening pr. aktie er vokset med 19,0 % om året de seneste 19 år. Laboratorios Farmaceuticos ROVIs nettoavance ligger på 18,9 %, ned fra 23,6 % for flere år siden. Laboratorios Farmaceuticos ROVI har i øjeblikket et direkteafkast på omkring 1,32 %. Udlodningsandelen er omkring 34 % af indtjeningen. Udbyttet er vokset med 15,7 % om året de seneste 17 år. Analytikernes mediankursmål er 85,07 EUR, hvilket er over den aktuelle kurs med 20,3 %. Af 16 analytikere anbefaler 13 køb — den samlede vurdering er Køb.
Laboratorios Farmaceuticos ROVI aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Laboratorios Farmaceuticos ROVI aktie og aktieanalyse
Hyppigt stillede spørgsmål om Laboratorios Farmaceuticos ROVI-aktien
The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.
Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.
The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.
Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.
Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 84,26 EUR for Laboratorios Farmaceuticos ROVI-aktien (median: 85,07 EUR), svarende til +21,3 % i forhold til seneste kurs. Konsensus bygger på 16 analytikervurderinger.
16 analytikere vurderer i øjeblikket Laboratorios Farmaceuticos ROVI-aktien: 13 anbefaler køb, 3 hold og 0 salg. For 2026 forventer analytikere, at Laboratorios Farmaceuticos ROVI genererer omsætning på 778,36 Mio. EUR og indtjening pr. aktie på 3,08 EUR.
Laboratorios Farmaceuticos ROVI-aktien (ROVI.MC) er noteret på 9 børser, herunder: London (0ILL.L), SIX (Zürich) (41L.SW), Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), Madrid (ROVI.MC).
Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.
forventet-omsætningen for Laboratorios Farmaceuticos ROVI er 778,36 Mio. EUR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Laboratorios Farmaceuticos ROVI er 157,78 Mio. EUR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Laboratorios Farmaceuticos ROVI er i øjeblikket 22,92. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Laboratorios Farmaceuticos ROVI-aktien.
Pris-til-salgs-forholdet (P/S) for Laboratorios Farmaceuticos ROVI er i øjeblikket 4,65. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Laboratorios Farmaceuticos ROVI-aktien.
AlleAktien-kvalitetsscore for Laboratorios Farmaceuticos ROVI er 7/10.
ISIN for Laboratorios Farmaceuticos ROVI er ES0157261019. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Laboratorios Farmaceuticos ROVI er A0M0GQ. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Laboratorios Farmaceuticos ROVI er ROVI.MC. Tickersymbolet bruges til at handle Laboratorios Farmaceuticos ROVI-aktier på børsen.
Laboratorios Farmaceuticos ROVI aktie
Laboratorios Farmaceuticos ROVI Peer Group
Laboratorios Farmaceuticos ROVI Ticker
Laboratorios Farmaceuticos ROVI FIGI
Alle fundamentale data om Laboratorios Farmaceuticos ROVI i deep dive
Vores aktieanalyse af Laboratorios Farmaceuticos ROVI-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Laboratorios Farmaceuticos ROVI. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: